Mean GH levels shown before and during octreotide treatment. The number of patients evaluated at each time point is shown in parentheses. Adapted with permission from Newman et al. Despite the established efficacy of octreotide acetate and its advantages over native somatostatin, the inconvenience of multiple daily subcutaneous injections to maintain therapeutic drug levels has remained a practical deterrent to both patients and physicians. Depot is administered as an intragluteal injection once every 28 days, a regimen which may be preferred by physicians to minimize compliance concerns.
Depot is generally well-tolerated with an established safety profile.
Treatment was monitored for 27 months. Treatment was monitored for 12 months. The primary efficacy variable in these trials was GH level. Adverse events and vital signs were also monitored. Based on GH levels, subsequent doses were reduced to 10 mg, increased to 30 mg, or maintained at 20 mg for an additional 9 months.